# An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS)

> **NCT01990248** · — · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 339 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01990248
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-23
- **Primary completion:** 2016-07-26
- **Final completion:** 2016-07-26
- **Target enrollment:** 339 (ACTUAL)
- **Last updated:** 2018-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01990248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01990248, "An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01990248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*